SFScott Ferguson

Scott Ferguson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Scott Ferguson has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury

    by Scott Ferguson, Benoit Mouzon, Daniel Paris, Destinee Aponte, Laila Abdullah, William Stewart, Michael Mullan, Fiona Crawford

    Traumatic brain injury (TBI) has chronic and long-term consequences for which there are currently no approved pharmacological treatments. We have previously characterized the chronic neurobehavioral and pathological sequelae of a mouse model of repetitive mild TBI (r-mTBI) through to 2 years post-TBI. Despite the mild nature of the initial insult, secondary injury processes are initiated that involve neuroinflammatory and neurodegenerative pathways persisting and progressing for weeks and months post-injury and providing a potential window of opportunity for therapeutic intervention. In this study we examined the efficacy of a novel anti-inflammatory compound, anatabine, in modifying outcome after TBI. Our model of r-mTBI involves a series of five mild impacts (midline impact at 5 m/sec, 1 mm strike depth, 200 msec dwell time) with an interval of 48 h. Anatabine treatment was administered starting 30 min after injury and was delivered continuously through drinking water. At 6 months after TBI, anatabine treatment improved spatial memory in injured mice. Nine months after TBI, a cohort of mice was euthanized for pathological analysis that revealed reductions in astroglial (glial fibrillary acid protein, GFAP) and microglial (ionized calcium-binding adapter molecule 1, IBA1) responses in treated, injured animals. Treatments for the remaining mice were then crossed-over to assess the effects of late treatment administration and the effects of treatment termination. Nine months following crossover the remaining mice showed no effect of injury on their spatial memory, and whereas pathological analysis showed improvements in mice that had received delayed treatment, corpus callosum IBA1 increased in post-crossover placebo r-mTBI mice. These data demonstrate efficacy of both early and late initiation of treatment with anatabine in improving long term behavioral and pathology outcomes after mild TBI. Future studies will characterize the treatment window, the time course of treatment needed, and the dose needed to achieve therapeutic levels of anatabine in humans after injury.


  • Plasma Lipidomic Profiling in a Military Population of Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder with Apolipoprotein E ɛ4–Dependent Effect

    by Tanja Emmerich, Laila Abdullah, Gogce Crynen, Michael Dretsch, James Evans, Ghania Ait-Ghenzala, Jon Reed, Hannah Montague, Helena Chaytow, Venkatarajan Mathura, et al.

    In the military population, there is high comorbidity between mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) due to the inherent risk of psychological trauma associated with combat. These disorders present with long-term neurological dysfunction and remain difficult to diagnose owing to their comorbidity and overlapping clinical presentation. Therefore, we performed cross-sectional analysis of blood samples from demographically matched soldiers (total n = 120) with mTBI, PTSD and mTBI + PTSD and those who were considered cognitively and psychologically normal. Soldiers were genotyped for apolipoprotein E (APOE) ε4 and phospholipids (PL) were examined using liquid chromatography/mass spectrometry (LC/MS) analysis. We observed significantly lower levels of several major PL classes in TBI, PTSD and TBI+PTSD compared to controls. PTSD severity analysis revealed that significant PL decreases were primarily restricted to the moderate-to-severe PTSD group. An examination of degree of unsaturation showed that monounsaturated fatty acid (MUFA) containing phosphatidylcholine (PC) and phosphatidylinositol (PI) species were lower in the TBI and TBI+PTSD groups. However these PLs were unaltered among PTSD subjects compared to controls. Similarly, ether PC (ePC) levels were lower in PTSD and TBI+PTSD subjects relative to controls. Ratios of arachidonic acid (AA) to docosahexaenoic acid (DHA) containing species were significantly decreased within PC and PE classes. APOE ε4 (+) subjects exhibited higher PL levels than their APOE ε4 (-) counterparts within same diagnostic groups. These findings suggest that PL profiles, together with APOE genotyping, could potentially aid to differentiate diagnosis of mTBI and PTSD and warrant further validation. In conclusion, PL profiling may facilitate clinical diagnosis of mTBI and PTSD, currently hindered by comorbid pathology and overlapping symptomology of these two conditions.


  • North American Brain Injury Societyʼs Ninth Annual Conference on Brain Injury

    by Fiona Crawford, Gogce Crynen, Jon Reed, Benoit Mouzon, Alex Bishop, Benjamin Katz, Scott Ferguson, John Phillips, Vani Ganapathi, Venkatarajan Mathura, et al.

  • Apolipoprotein E genotype and oxidative stress response to traumatic brain injury

    by S. Ferguson, B. Mouzon, G. Kayihan, M. Wood, F. Poon, S. Doore, V. Mathura, J. Humphrey, B. O'STeen, R. Hayes, et al.